Clinical trials: Symptoms Cold
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
The aim of the study is to assess the safety of inhaled SNG001 and the ability of inhaled SNG001 to 'switch on' the cells' anti-viral defences in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03570359
- Testing
- Interferon Beta-1A
- Where
- 16 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- Synairgen Research Ltd.
Healthy Volunteers
A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study
The study design of this trial is a Dose-Block Randomized, Placebo controlled (Double-blind), Active Controlled(Open-label), Dose-escalation.
- Trial name
- NCT02175056
- Testing
- HL2351, Kineret(Anakinra)
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Covid19
Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients
The current study will investigate the tolerability and efficacy of inhaled Carragelose® versus saline in hospitalized COVID-19 patients.
- Trial name
- NCT04793984
- Testing
- Carragelose, NaCl
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Marinomed Biotech AG
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Lower Respiratory Tract Infection, Upper Respiratory Tract Infection
Antiviral Activity of Oral Probiotics
The aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed S. salivarius probiotic in a powder format.
- Trial name
- NCT05374070
- Testing
- Streptococcus salivarius K12 Powder 1 Billion colony forming units /g), Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included, Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)
- Where
- New Zealand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- John Hale
Cryopyrin-Associated Periodic Syndromes (CAPS)
HL2351 CAPS Phase II Study
This is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).
- Trial name
- NCT02853084
- Testing
- HL2351
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Handok Inc.
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
OM336 in Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
- Conditions
- AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
- Trial name
- NCT07083960
- Testing
- OM336
- Where
- 7 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Lakefront Biotherapeutics West LLC
Acute Upper Respiratory Tract Infection
Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections
The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by immediate release (IR) guaifenesin (GGE) and do not match approved Mucinex labeling in the U.S.
- Trial name
- NCT01537081
- Testing
- Mucinex, Immediate-release Guaifenesin
- Where
- 43 sites in United States
- Volunteers
- 2,810 people
- Sponsor
- Reckitt Benckiser LLC
URTI, Common Cold
A Novel Cold and Flu Herbal Blend for Reducing the Duration and Severity of the Common Cold
The aim of this study is to evaluate the efficacy of a Novel Herbal Cold \& Flu Blend in reducing the duration of symptoms of the common cold.
- Trial name
- NOURTI (NCT07642648)
- Testing
- Novel Herbal Cold & Flu Blend
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Common Cold, Allergy
Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)
Healsea® Children is a seawater-based nasal spray supplemented with a natural Symbiofilm® extract (0.02%) isolated from marine bacteria.
- Trial name
- NCT05034328
- Testing
- Healsea® Children, Conventional therapies for common cold
- Where
- 15 sites in Poland
- Volunteers
- 186 people
- Sponsor
- Lallemand Pharma AG
Upper Respiratory Infections
Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting
The purpose of this study is to assess the accuracy and ease-of-use of a simplified FilmArray Respiratory Panel test (FilmArray RP EZ) when performed according to the manufacturer's instructions by personnel in laboratories…
- Trial name
- NCT02232711
- Where
- 4 sites in United States
- Volunteers
- 1,082 people
- Sponsor
- BioFire Diagnostics, LLC
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
The purpose of this study is to evaluate the safety and efficacy of the Biologic Lung Volume Reduction System (BLVR) for patients with advanced emphysema refractory to medical therapy.
- Trial name
- NCT00517998
- Testing
- Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Aeris Therapeutics
SARS-CoV2 Infection (COVID-19), URTI - Viral Upper Respiratory Tract Infection
Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load.
Prospective, randomized, controlled, multicenter, parallel clinical trial to assess the efficacy of seawater nasal wash to relieve COVID-19 and URTIs nasal symptoms and reduce intranasal viral load in subjects with mild to…
- Trial name
- SeaCare (NCT04916639)
- Testing
- Device: Physiomer undiluted seawater nasal spray
- Where
- France
- Volunteers
- 370 people
- Sponsor
- Laboratoire de la Mer
Cryopyrin-associated Periodic Syndromes (CAPS)
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)
- Trial name
- NCT07247266
- Testing
- JTE-162
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Akros Pharma Inc.
Bronchitis, Cough
Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution
This observational, non-interventional multicentric study compares the inhalation therapy on patients suffering on respiratory tract infections and/or acute bronchitis between Ectoin inhalation solution and Pari NaCl (0.9%)…
- Conditions
- Bronchitis, Cough, Sputum, Cellular Atypia, Dyspnoea
- Trial name
- NCT02632851
- Where
- Germany
- Volunteers
- 135 people
- Sponsor
- Bitop AG
Common Cold
Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common Cold
The purpose of the study will be to assess the efficacy and safety of XIGO administered orally, three times a day, compared with placebo in patients with the common cold.
- Trial name
- NCT01092039
- Testing
- lactoferrin, L-Glutamine and beta-glucans
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Xigo Health LLC
Cough, Upper Respiratory Infection
A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection
Cough is a frequent symptom in children and infants and is one of the most common reasons parents visit a healthcare provider for their child.
- Conditions
- Cough, Upper Respiratory Infection, Nocturnal Cough
- Trial name
- NCT01588249
- Testing
- Pasteurized maple syrup
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Zarbee's Inc.
Common Cold/Flu, Nasal Congestion
Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults
Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.
- Conditions
- Common Cold/Flu, Nasal Congestion, Nasal Obstruction
- Trial name
- PANAMA (NCT07626437)
- Testing
- dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg, dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg
- Where
- 15 sites in Brazil
- Volunteers
- 620 people
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS)
Ilaris NIS in Korea
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes…
- Conditions
- Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
- Trial name
- REASSURE (NCT06838143)
- Testing
- Ilaris
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inducible Urticaria
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).
- Trial name
- NCT05976243
- Testing
- Remibrutinib
- Where
- 130 sites in United States, Argentina and 26 more
- Volunteers
- 362 people
- Sponsor
- Novartis Pharmaceuticals